Buy Retatrutide Pen – Research Peptide | PEPTEX
Lipidated 36-residue synthetic peptide. CAS 2381089-83-2. Purity ≥98% by HPLC and MS. Contains a C20 fatty diacid chain conferring albumin-binding properties and prolonged half-life. Supplied as a sterile lyophilised powder in a sealed borosilicate glass vial with a sterile diluent vial. Intended for laboratory and research purposes only. Store at −20°C; protect from light and moisture.
Price: EUR | Brand: PEPTEX | In Stock | EU-wide delivery, 3-5 business days
Rating: 4.9/5 (454 reviews)
Customer Reviews
Isabel — ★★★★★
Fourth pen. Every batch is identical. The reta effect on metabolism is something you can measure (higher resting energy expenditure) and the pen format means I never skip a dose. Peptex quality is perfect.
Astrid L. — ★★★★★
Switched from the vial to the pen mid-cycle. Identical effects, zero disruption. The pen format makes sense especially for retat which requires careful weekly dosing. No room for reconstitution errors.
sam.w — ★★★★★
Ordered both the tirze and retat pens from peptex. Tried tirzepatide first for 3 months, then switched to retat. The pen format made the transition seamless. Both pens are excellent quality.
Damien — ★★★★★
Third pen order. The triple agonist mechanism (GLP-1 + GIP + glucagon) delivers results that tirze alone couldn't match for me. Having it in a pen format removes the last friction point. Peptex quality is excellent.
Eva M. — ★★★★
Effective product in a convenient format. The thermogenic effect from the glucagon component is more noticeable than with tirzepatide pen. Minor: wish the pen capacity was slightly larger for higher dose phases.
Available Sizes
- 30mg — 269 EUR
- 60mg — 399 EUR
Research References
- Triple-Hormone-Receptor Agonist Reta (RTT) for Obesity — Phase 2 Trial — NEJM / PubMed (2023)
- Reta (RTT), a GIP/GLP-1/glucagon agonist, for type 2 diabetes — Phase 2 — Lancet / PubMed (2023)
💬 Комментарии